Robert Hofmeister

Chief Scientific Officer at CREATE Medicines

Speaker

Robert Hofmeister, PhD

Chief Scientific Officer

Robert Hofmeister, PhD is Chief Scientific Officer at CREATE Medicines, where he leads the development of in vivo CAR and mRNA-based immunotherapies. He joined the company in 2024, bringing more than two decades of experience in immuno-oncology, cell therapy, and drug development.

Prior to CREATE Medicines, Dr Hofmeister served as CSO at Resonance Medicine, where he guided the company’s R&D strategy to advance therapeutic proteases. He previously was CSO at TCR² Therapeutics, where he played a central role in building the R&D organization from the early beginnings and advancing the TRuC®-T cell platform into the clinic.

Earlier in his career, Hofmeister contributed to the development of key immuno-oncology therapies at EMD Serono including the now approved Bavencio® (avelumab) and helped advance the bispecific antibody Blincyto® (blinatumomab) during his time at Micromet AG (now part of Amgen).

Dr Hofmeister received his PhD from the University of Regensburg in Germany, where he studied the signaling of the cytokine interleukin-1. He continued to work in the cytokine field as a postdoctoral fellow at the National Cancer Institute.